



Clinical trial results:

A Phase 2-3 Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) versus Placebo in Patients with Advanced Unresectable Dedifferentiated Liposarcoma (DDLs)

Summary

EudraCT number	2015-003594-14
Trial protocol	GB DE FR ES SE BE IT
Global end of trial date	26 October 2021

Results information

Result version number	v1 (current)
This version publication date	21 January 2023
First version publication date	21 January 2023

Trial information

Trial identification

Sponsor protocol code	KCP-330-020
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02606461
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Karyopharm Therapeutics Inc.
Sponsor organisation address	85 Wells Avenue, Newton, MA, United States, 02459
Public contact	Clinical Trial Information, Karyopharm Therapeutics, Inc., +1 617658 0600, clinicaltrials@karyopharm.com
Scientific contact	Clinical Trial Information, Karyopharm Therapeutics, Inc., +1 617658 0600, clinicaltrials@karyopharm.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	26 October 2021
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	26 October 2021
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The main objective of the Phase 2 was to assess and compare progression-free Survival (PFS) of subjects with advanced unresectable dedifferentiated Liposarcoma (DDLs) treated with selinexor (60 milligram [mg]) or placebo twice weekly and Phase 3 was to assess and compare PFS of subjects with advanced unresectable DDLs treated with selinexor (60 mg) or placebo twice weekly.

Protection of trial subjects:

The study was conducted in accordance with the ethical principles originating in the Declaration of Helsinki in place at the time of study conduct. The study was conducted in compliance with the International Council for Harmonisation (ICH) E6 Guideline for Good Clinical Practice (GCP) (Committee for Proprietary Medicinal Products [CPMP] guideline CPMP/ICH/135/95), United States Code of Federal Code of Regulations, and all applicable local regulatory requirements.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	04 January 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Canada: 27
Country: Number of subjects enrolled	United States: 175
Country: Number of subjects enrolled	Israel: 3
Country: Number of subjects enrolled	Spain: 34
Country: Number of subjects enrolled	Sweden: 3
Country: Number of subjects enrolled	United Kingdom: 12
Country: Number of subjects enrolled	Belgium: 4
Country: Number of subjects enrolled	France: 37
Country: Number of subjects enrolled	Germany: 10
Country: Number of subjects enrolled	Italy: 37
Worldwide total number of subjects	342
EEA total number of subjects	125

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	174
From 65 to 84 years	168
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The study was conducted at 71 sites in the United States, Canada, Germany, Belgium, Israel, United Kingdom, France, Spain, Italy, and Sweden. A total of 342 subjects were enrolled, out of which 57 subjects were randomised to receive study treatment in Phase 2 and 285 subjects randomised, of which 284 subjects received study treatment in Phase 3.

Pre-assignment

Screening details:

This study consisted of 2 Phases (2 and 3), where subjects were randomised to selinexor or placebo in double-blind treatment. Subjects in the placebo group who had progressive disease (PD) during the Phase 2 and 3 double-blinded treatment, could crossover to open-label selinexor treatment.

Period 1

Period 1 title	Period 1: Double-blinded Period
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Phase 2 Double-blinded: selinexor

Arm description:

Subjects received a fixed blinded dose of 60 milligrams (mg) selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle.

Arm type	Experimental
Investigational medicinal product name	Selinexor
Investigational medicinal product code	
Other name	KPT-330
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received a fixed blinded dose of 60 mg Selinexor twice weekly on Day 1 and 3.

Arm title	Phase 2 Double-blinded: placebo
------------------	---------------------------------

Arm description:

Subjects received a fixed blinded dose of placebo matched to selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle.

Arm type	Experimental
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received a fixed blinded dose of placebo matched to Selinexor twice weekly on Day 1 and 3.

Arm title	Phase 3 Double-blinded: selinexor
------------------	-----------------------------------

Arm description:

Subjects received a fixed blinded dose of 60 mg selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Selinexor
Investigational medicinal product code	
Other name	KPT-330
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received a fixed blinded dose of 60 mg Selinexor twice weekly on Day 1 and 3.

Arm title	Phase 3 Double-blinded: placebo
------------------	---------------------------------

Arm description:

Subjects received a fixed blinded dose of placebo matched to selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle.

Arm type	Active comparator
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received a fixed blinded dose of placebo matched to Selinexor twice weekly on Day 1 and 3.

Number of subjects in period 1	Phase 2 Double-blinded: selinexor	Phase 2 Double-blinded: placebo	Phase 3 Double-blinded: selinexor
Started	27	30	188
Completed	27	30	187
Not completed	0	0	1
Randomised but no treatment	-	-	1

Number of subjects in period 1	Phase 3 Double-blinded: placebo
Started	97
Completed	97
Not completed	0
Randomised but no treatment	-

Period 2

Period 2 title	Period 2: Open Label Period
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	No
------------------------------	----

Arm title	Phase 2: Open Label- selinexor
Arm description: Subjects in the placebo group who had PD during Phase 2 double-blinded treatment were entered in open label and received selinexor 60 mg tablet twice-weekly during Weeks 1 to 6 of each 6-week (42-day) cycle.	
Arm type	Experimental
Investigational medicinal product name	Selinexor
Investigational medicinal product code	
Other name	KPT-330
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subject received 60 mg Selinexor tablet twice-weekly during Weeks 1 to 6.

Arm title	Phase 3: Open Label- selinexor
Arm description: Subjects in the placebo group who had PD during Phase 3 double-blinded treatment, were entered in open label and received selinexor 60 mg tablet twice-weekly during Weeks 1 to 6 of each 6-week (42-day) cycle.	
Arm type	Experimental
Investigational medicinal product name	Selinexor
Investigational medicinal product code	
Other name	KPT-330
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subject received 60 mg Selinexor tablet twice-weekly during Weeks 1 to 6.

Number of subjects in period 2	Phase 2: Open Label- selinexor	Phase 3: Open Label- selinexor
Started	24	63
Completed	24	63

Baseline characteristics

Reporting groups

Reporting group title	Phase 2 Double-blinded: selinexor
Reporting group description:	
Subjects received a fixed blinded dose of 60 milligrams (mg) selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle.	
Reporting group title	Phase 2 Double-blinded: placebo
Reporting group description:	
Subjects received a fixed blinded dose of placebo matched to selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle.	
Reporting group title	Phase 3 Double-blinded: selinexor
Reporting group description:	
Subjects received a fixed blinded dose of 60 mg selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle.	
Reporting group title	Phase 3 Double-blinded: placebo
Reporting group description:	
Subjects received a fixed blinded dose of placebo matched to selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle.	

Reporting group values	Phase 2 Double-blinded: selinexor	Phase 2 Double-blinded: placebo	Phase 3 Double-blinded: selinexor
Number of subjects	27	30	188
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	19	17	92
From 65-84 years	8	13	96
85 years and over	0	0	0
Gender categorical			
Units: Subjects			
Female	12	11	74
Male	15	19	114
Ethnicity			
Units: Subjects			
Hispanic or Latino	2	3	7
Not Hispanic or Latino	25	25	149
Unknown or Not Reported	0	2	32
Race			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	2	5	9
Native Hawaiian or Other Pacific Islander	1	0	2
Black or African American	1	2	3

White	23	20	139
More than one race	0	3	34
Unknown or Not Reported	0	0	1

Reporting group values	Phase 3 Double-blinded: placebo	Total	
Number of subjects	97	342	
Age categorical Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	46	174	
From 65-84 years	51	168	
85 years and over	0	0	
Gender categorical Units: Subjects			
Female	33	130	
Male	64	212	
Ethnicity Units: Subjects			
Hispanic or Latino	6	18	
Not Hispanic or Latino	79	278	
Unknown or Not Reported	12	46	
Race Units: Subjects			
American Indian or Alaska Native	0	0	
Asian	3	19	
Native Hawaiian or Other Pacific Islander	0	3	
Black or African American	1	7	
White	80	262	
More than one race	13	50	
Unknown or Not Reported	0	1	

End points

End points reporting groups

Reporting group title	Phase 2 Double-blinded: selinexor
Reporting group description: Subjects received a fixed blinded dose of 60 milligrams (mg) selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle.	
Reporting group title	Phase 2 Double-blinded: placebo
Reporting group description: Subjects received a fixed blinded dose of placebo matched to selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle.	
Reporting group title	Phase 3 Double-blinded: selinexor
Reporting group description: Subjects received a fixed blinded dose of 60 mg selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle.	
Reporting group title	Phase 3 Double-blinded: placebo
Reporting group description: Subjects received a fixed blinded dose of placebo matched to selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle.	
Reporting group title	Phase 2: Open Label- selinexor
Reporting group description: Subjects in the placebo group who had PD during Phase 2 double-blinded treatment were entered in open label and received selinexor 60 mg tablet twice-weekly during Weeks 1 to 6 of each 6-week (42-day) cycle.	
Reporting group title	Phase 3: Open Label- selinexor
Reporting group description: Subjects in the placebo group who had PD during Phase 3 double-blinded treatment, were entered in open label and received selinexor 60 mg tablet twice-weekly during Weeks 1 to 6 of each 6-week (42-day) cycle.	

Primary: Phase 3 Double Blind: Progression-free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

End point title	Phase 3 Double Blind: Progression-free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 ^[1]
End point description: PFS was defined as the time from the date of randomisation until the first date of Independent Review Committee (IRC)-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20% increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. Phase 3 Intent-to-Treat Population (Ph3-ITT) consisted of all subjects randomised to study treatment in Phase 3, regardless of whether or not they received study treatment.	
End point type	Primary
End point timeframe: From the date of randomisation until the first date of disease progression, or death due to any cause whichever occurred first (up to 57 months)	

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Data was assessed and reported for the specific phase only.

End point values	Phase 3 Double- blinded: selinexor	Phase 3 Double- blinded: placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	188	97		
Units: Months				
median (confidence interval 90%)	2.83 (2.73 to 4.11)	2.07 (1.51 to 3.06)		

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Phase 3 Double-blinded: selinexor v Phase 3 Double-blinded: placebo
Number of subjects included in analysis	285
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0114
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.7026
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.5191
upper limit	0.9509

Primary: Phase 3 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.1

End point title	Phase 3 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.1 ^[2]
-----------------	--

End point description:

PFS was defined as the time from the date of randomisation in the Phase 3 open-label period until the first date of IRC-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. The Phase 3 Open-Label Population (Ph3-OL) consisted of all subjects in Phase 3 who were randomised to placebo in the blinded phase, entered the open-label period, and received at least one dose of open-label selinexor.

End point type	Primary
----------------	---------

End point timeframe:

From the date of randomisation in phase 3 open label period until the first date of disease progression, or death due to any cause whichever occurred first (up to 57 months)

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical testing was performed for the primary end point.

End point values	Phase 3: Open Label-selinexor			
Subject group type	Reporting group			
Number of subjects analysed	63			
Units: Months				
median (confidence interval 95%)	2.73 (1.97 to 4.14)			

Statistical analyses

No statistical analyses for this end point

Primary: Phase 2 Double Blind: Progression-free Survival (PFS) as Per RECIST Version 1.1

End point title	Phase 2 Double Blind: Progression-free Survival (PFS) as Per RECIST Version 1.1 ^[3]
-----------------	--

End point description:

PFS was defined as the time from date of randomisation until the first date of IRC-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. The Phase 2 Intent-to-Treat Population (Ph2-ITT) consisted of all subjects randomised to study treatment in Phase 2, regardless of whether or not they received study treatment. Here '99999' signifies that data could not be estimated due to higher number (>50%) of deaths.

End point type	Primary
----------------	---------

End point timeframe:

From date of randomisation until the first date of PD or death due to any cause, whichever occurred first (up to 57 months)

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Data was assessed and reported for the specific phase only.

End point values	Phase 2 Double-blinded: selinexor	Phase 2 Double-blinded: placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	27	30		
Units: Months				
median (confidence interval 95%)	3.02 (1.41 to 99999)	2.76 (1.58 to 99999)		

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Phase 2 Double-blinded: selinexor v Phase 2 Double-blinded: placebo

Number of subjects included in analysis	57
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6051
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1.1521
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.5357
upper limit	2.4778

Primary: Phase 2 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.1

End point title	Phase 2 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.1 ^[4]
-----------------	--

End point description:

PFS was defined as the time from date of randomisation in the Phase 2 open-label period until the first date of IRC-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. The Phase 2 Open-Label Population (Ph2-OL) consisted of all subjects in Phase 2 who were randomised to placebo in the blinded phase, entered open-label period, and received at least one dose of open-label selinexor.

End point type	Primary
----------------	---------

End point timeframe:

From date of randomisation in the Phase 2 open label period until the first date of PD or death due to any cause, whichever occurred first (up to 57 months)

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical testing was performed for the primary end point.

End point values	Phase 2: Open Label-selinexor			
Subject group type	Reporting group			
Number of subjects analysed	24			
Units: Months				
median (confidence interval 95%)	1.38 (1.38 to 2.27)			

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 3 Double Blind: Overall Survival (OS)

End point title	Phase 3 Double Blind: Overall Survival (OS) ^[5]
-----------------	--

End point description:

OS was defined as the duration (in months) from the date of randomisation to death from any cause.

Subject last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier. The Ph3-ITT consisted of all subjects randomised to study treatment in Phase 3, regardless of whether or not they received study treatment.

End point type	Secondary
----------------	-----------

End point timeframe:

From date of randomisation until death due to any cause, whichever occurred first (up to 70 months)

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Data was assessed and reported for the specific phase only.

End point values	Phase 3 Double- blinded: selinexor	Phase 3 Double- blinded: placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	188	97		
Units: Months				
median (confidence interval 95%)	10.38 (8.41 to 13.40)	12.71 (8.54 to 15.90)		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 3 Open Label: Overall Survival (OS)

End point title	Phase 3 Open Label: Overall Survival (OS)
-----------------	---

End point description:

OS was defined as the duration (in months) from the date of randomisation in the Phase 3 open-label period to death from any cause. Subjects last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier. The Ph3-OL consisted of all Subjects in Phase 3 who were randomised to placebo in the blinded phase, entered the open-label period, and received at least one dose of open-label selinexor.

End point type	Secondary
----------------	-----------

End point timeframe:

From date of randomisation in phase 3 open label period until death due to any cause, whichever occurred first (up to 70 months)

End point values	Phase 3: Open Label- selinexor			
Subject group type	Reporting group			
Number of subjects analysed	63			
Units: Months				
median (confidence interval 95%)	10.18 (5.78 to 14.69)			

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2 Double Blind: Overall Survival (OS)

End point title	Phase 2 Double Blind: Overall Survival (OS) ^[6]
-----------------	--

End point description:

OS was defined as the duration (in months) from the date of randomisation to death from any cause. Subjects last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier. The Ph2-ITT consisted of all subjects randomised to study treatment in Phase 2, regardless of whether or not they received study treatment.

End point type	Secondary
----------------	-----------

End point timeframe:

From the date of randomisation until death due to any cause, whichever occurred first (up to 70 months)

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Data was assessed and reported for the specific phase only.

End point values	Phase 2 Double-blinded: selinexor	Phase 2 Double-blinded: placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	27	30		
Units: Months				
median (confidence interval 95%)	17.31 (10.51 to 29.57)	16.07 (8.38 to 23.06)		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2 Open Label: Overall Survival (OS)

End point title	Phase 2 Open Label: Overall Survival (OS)
-----------------	---

End point description:

OS was defined as the duration (in months) from the date of randomisation in the Phase 2 open-label period to death from any cause. Subjects last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier. The Ph2-OL consisted of all subjects in Phase 2 who were randomised to placebo in the blinded phase, entered the open-label period, and received at least one dose of open-label selinexor.

End point type	Secondary
----------------	-----------

End point timeframe:

From date of randomisation in the Phase 2 open-label period until death due to any cause, whichever occurred first (up to 70 months)

End point values	Phase 2: Open Label-selinexor			
Subject group type	Reporting group			
Number of subjects analysed	24			
Units: Months				
median (confidence interval 95%)	8.90 (4.96 to 18.92)			

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 3 Double Blind: Time-to-Progression (TTP) as Per RECIST Version 1.1

End point title	Phase 3 Double Blind: Time-to-Progression (TTP) as Per RECIST Version 1.1 ^[7]
-----------------	--

End point description:

TTP was defined as the time from date of randomisation until ICR determined PD as per RECIST version 1.1, or death due to disease progression, whichever occurred first. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. The Ph3-ITT consisted of all subjects randomised to study treatment in Phase 3, regardless of whether or not they received study treatment.

End point type	Secondary
----------------	-----------

End point timeframe:

From date of randomisation until the first date of PD or death due to any cause, whichever occurred first (up to 70 months)

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Data was assessed and reported for the specific phase only.

End point values	Phase 3 Double-blinded: selinexor	Phase 3 Double-blinded: placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	188	97		
Units: Months				
median (confidence interval 95%)	2.83 (2.73 to 4.11)	2.10 (1.51 to 3.06)		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 3 Open Label: Time-to-Progression (TTP) as Per RECIST Version 1.1

End point title	Phase 3 Open Label: Time-to-Progression (TTP) as Per RECIST Version 1.1
-----------------	---

End point description:

TTP was defined as the time from date of randomization in the Phase 3 open-label period until ICR-determined PD per RECIST version 1.1, or death due to disease progression, whichever occurred first. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. The Ph3-OL consisted of all subjects in Phase 3 who were randomised to placebo in the blinded phase, entered the open-label period and received at least one dose of open-label selinexor.

End point type	Secondary
----------------	-----------

End point timeframe:

From date of randomisation in the Phase 3 open label-period until the first date of PD or death due to any cause, whichever occurred first (up to 70 months)

End point values	Phase 3: Open Label-selinexor			
Subject group type	Reporting group			
Number of subjects analysed	63			
Units: Months				
median (confidence interval 95%)	2.73 (1.97 to 4.14)			

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2 Double Blind: Time-to-Progression (TTP) as Per RECIST Version 1.1

End point title	Phase 2 Double Blind: Time-to-Progression (TTP) as Per RECIST Version 1.1 ^[8]
-----------------	--

End point description:

TTP was defined as the time from date of randomisation until ICR-determined PD as per RECIST version 1.1, or death due to disease progression, whichever occurred first. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. The Ph2-ITT consisted of all subjects randomised to study treatment in Phase 2, regardless of whether or not they received study treatment. Here '99999' signifies that data could not be estimated due to the higher number (>50%) of deaths.

End point type	Secondary
----------------	-----------

End point timeframe:

From date of randomisation until the first date of PD or death due to any cause, whichever occurred first (up to 70 months)

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Data was assessed and reported for the specific phase only.

End point values	Phase 2 Double-blinded: selinexor	Phase 2 Double-blinded: placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	27	30		
Units: Months				

median (confidence interval 95%)	3.02 (1.41 to 99999)	2.76 (1.58 to 99999)		
----------------------------------	----------------------	----------------------	--	--

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2 Open Label: Time-to-Progression (TTP) as Per RECIST Version 1.1

End point title	Phase 2 Open Label: Time-to-Progression (TTP) as Per RECIST Version 1.1
-----------------	---

End point description:

TTP was defined as the time from date of randomisation in the Phase 2 open-label period until ICR-determined PD per RECIST version 1.1, or death due to disease progression, whichever occurred first. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. The Ph2-OL consisted of all subjects in Phase 2 who were randomised to placebo in the blinded phase, entered the open-label period and received at least one dose of open-label selinexor.

End point type	Secondary
----------------	-----------

End point timeframe:

From date of randomisation in the Phase 2 open-label period until the first date of PD or death due to any cause, whichever occurred first (up to 70 months)

End point values	Phase 2: Open Label-selinexor			
Subject group type	Reporting group			
Number of subjects analysed	24			
Units: Months				
median (confidence interval 95%)	1.38 (1.38 to 2.27)			

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 3 Double Blind: Overall Response Rate (ORR)

End point title	Phase 3 Double Blind: Overall Response Rate (ORR) ^[9]
-----------------	--

End point description:

ORR was defined as the percentage of subjects who achieved complete response (CR) or partial response (PR), per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The Ph3-ITT consisted of all subjects randomised to study treatment in Phase 3, regardless of whether or not they received study treatment. Here '99999' signifies that data could not be evaluated due to no events of CR and PR in placebo arm.

End point type	Secondary
----------------	-----------

End point timeframe:

From date of randomisation until the documentation of CR or PR (up to 70 months)

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Data was assessed and reported for the specific phase only.

End point values	Phase 3 Double- blinded: selinexor	Phase 3 Double- blinded: placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	188	97		
Units: Percentage of subjects				
number (confidence interval 95%)	2.7 (0.9 to 6.1)	99999 (99999 to 99999)		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 3 Open Label: Overall Response Rate (ORR)

End point title	Phase 3 Open Label: Overall Response Rate (ORR)
-----------------	---

End point description:

ORR was defined as the percentage of subjects who achieved CR or PR, per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The Ph3-OL consisted of all subjects in Phase 3 who were randomised to placebo in blinded phase, entered open-label period and received at least one dose of open-label selinexor.

End point type	Secondary
----------------	-----------

End point timeframe:

From date of randomisation in phase 3 open label period until the documentation of CR or PR (up to 70 months)

End point values	Phase 3: Open Label- selinexor			
Subject group type	Reporting group			
Number of subjects analysed	63			
Units: Percentage of subjects				
number (confidence interval 95%)	3.2 (0.4 to 11)			

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2 Double Blind: Overall Response Rate (ORR)

End point title	Phase 2 Double Blind: Overall Response Rate (ORR) ^[10]
End point description:	
ORR was defined as the percentage of subjects who achieved CR or PR, per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The Ph2-ITT consisted of all subjects randomised to study treatment in Phase 2, regardless of whether or not they received study treatment. Here '99999' signifies that data could not be evaluated since no subjects had CR or PR.	
End point type	Secondary
End point timeframe:	
From date of randomisation until the documentation of CR or PR (up to 70 months)	
Notes:	
[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.	
Justification: Data was assessed and reported for the specific phase only.	

End point values	Phase 2 Double-blinded: selinexor	Phase 2 Double-blinded: placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	27	30		
Units: Percentage of subjects				
number (confidence interval 95%)	99999 (99999 to 99999)	99999 (99999 to 99999)		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2 Open Label: Overall Response Rate (ORR)

End point title	Phase 2 Open Label: Overall Response Rate (ORR)
End point description:	
ORR was defined as the percentage of subjects who achieved CR or PR, per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The Ph2-OL consisted of all subjects in Phase 2 who were randomised to placebo in the blinded phase, entered the open-label period and received at least one dose of open-label selinexor. Data could not be evaluated due to no CR or PR events.	
End point type	Secondary
End point timeframe:	
From date of randomisation in the Phase 2 open label period until the documentation of CR or PR (up to 70 months)	

End point values	Phase 2: Open Label-selinexor			
Subject group type	Reporting group			
Number of subjects analysed	24			
Units: percentage of subjects				
number (not applicable)				
Subjects who achieved CR	0			
Subjects who achieved PR	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 3 Double Blind: Duration of Response (DOR)

End point title	Phase 3 Double Blind: Duration of Response (DOR) ^[11]
-----------------	--

End point description:

DOR was defined as the time from first occurrence of CR or PR until the first date of PD per RECIST version 1.1 or death. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. Ph3-ITTSet. Here, 'number of subjects analysed' signifies those who had CR and PR in specified group/arm and phase. Here, '99999 and 00000' signifies that upper and lower limit of 95% CI was not estimable due to lesser number of subjects with events.

End point type	Secondary
----------------	-----------

End point timeframe:

From first occurrence of CR or PR until the first date of PD (up to 70 months)

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Data was assessed and reported for the specific phase only.

End point values	Phase 3 Double-blinded: selinexor	Phase 3 Double-blinded: placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	5	0 ^[12]		
Units: Months				
number (confidence interval 95%)	7.39 (00000 to 99999)	(to)		

Notes:

[12] - Data could not be evaluated due to no events of CR and PR.

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 3 Double Blind: Progression-free Survival (PFS) as Per Investigator Assessment

End point title	Phase 3 Double Blind: Progression-free Survival (PFS) as Per Investigator Assessment ^[13]
End point description: PFS was defined as the time from date of randomisation until the first date of PD, per RECIST version 1.1, or death due to any cause as defined by the Investigator based on clinical and/or radiologic criteria. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. The Ph3-ITT consisted of all subjects randomised to study treatment in Phase 3, regardless of whether or not they received study treatment.	
End point type	Secondary
End point timeframe: From the date of randomisation until the first date of disease progression, or death due to any cause, whichever occurred first (up to 70 months)	
Notes: [13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Data was assessed and reported for the specific phase only.	

End point values	Phase 3 Double-blinded: selinexor	Phase 3 Double-blinded: placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	188	97		
Units: Months				
median (confidence interval 95%)	2.89 (2.76 to 4.17)	1.87 (1.45 to 2.89)		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 3 Double Blind: Time to Next Treatment (TTNT)

End point title	Phase 3 Double Blind: Time to Next Treatment (TTNT) ^[14]
End point description: TTNT was defined as time since randomisation until the first new antineoplastic therapy or death due to any cause, whichever occurs first. The Ph3-ITT consisted of all subjects randomised to study treatment in Phase 3, regardless of whether or not they received study treatment.	
End point type	Secondary
End point timeframe: Time from randomisation to the first new antineoplastic therapy or death due to any cause (up to 70 months)	
Notes: [14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Data was assessed and reported for the specific phase only.	

End point values	Phase 3 Double-blinded: selinexor	Phase 3 Double-blinded: placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	188	97		
Units: Months				

median (confidence interval 95%)	5.42 (4.67 to 6.34)	3.22 (2.56 to 3.78)		
----------------------------------	---------------------	---------------------	--	--

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2 Double Blind: Time to Next Treatment (TTNT)

End point title	Phase 2 Double Blind: Time to Next Treatment (TTNT) ^[15]
-----------------	---

End point description:

TTNT was defined as time since randomisation until the first new antineoplastic therapy or death due to any cause, whichever occurs first. The Ph2-ITT consisted of all subjects randomised to study treatment in Phase 2, regardless of whether or not they received study treatment.

End point type	Secondary
----------------	-----------

End point timeframe:

Time from randomisation to the first new antineoplastic therapy or death due to any cause (up to 70 months)

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Data was assessed and reported for the specific phase only.

End point values	Phase 2 Double-blinded: selinexor	Phase 2 Double-blinded: placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	27	30		
Units: Months				
median (confidence interval 95%)	4.96 (3.91 to 14.03)	2.92 (2.04 to 5.06)		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 3 Double Blind: Number of Subjects with Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

End point title	Phase 3 Double Blind: Number of Subjects with Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs ^[16]
-----------------	---

End point description:

An adverse events was defined as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product or placebo and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious

TEAEs. Phase 3 Safety Population (Ph3-SAF) was included.

End point type	Secondary
----------------	-----------

End point timeframe:

From start of study drug administration up to 70 months

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Data was assessed and reported for the specific phase only.

End point values	Phase 3 Double- blinded: selinexor	Phase 3 Double- blinded: placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	187	97		
Units: subjects				
Subjects with TEAEs	187	94		
Subjects with Serious TEAEs	73	18		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 3 Open Label: Number of Subjects with TEAEs and Serious TEAEs

End point title	Phase 3 Open Label: Number of Subjects with TEAEs and Serious TEAEs
-----------------	---

End point description:

A adverse events was defined as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product or placebo and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. A SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs. Ph3-OL Population was included.

End point type	Secondary
----------------	-----------

End point timeframe:

From start of study drug administration up to 70 months

End point values	Phase 3: Open Label- selinexor			
Subject group type	Reporting group			
Number of subjects analysed	63			
Units: Subjects				
Subjects with TEAEs	63			
Subjects with Serious TEAEs	25			

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2 Double Blind: Number of Subjects with TEAEs and Serious TEAEs

End point title	Phase 2 Double Blind: Number of Subjects with TEAEs and Serious TEAEs ^[17]
-----------------	---

End point description:

A adverse events was defined as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product or placebo and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs. Phase 2 Safety Population was included.

End point type	Secondary
----------------	-----------

End point timeframe:

From start of study drug administration up to 70 months

Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Data was assessed and reported for the specific phase only.

End point values	Phase 2 Double-blinded: selinexor	Phase 2 Double-blinded: placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	27	30		
Units: Subjects				
Subject with TEAEs	27	29		
Subjects with Serious TEAEs	4	6		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2 Open Label: Number of Subjects with TEAEs and Serious TEAEs

End point title	Phase 2 Open Label: Number of Subjects with TEAEs and Serious TEAEs
-----------------	---

End point description:

A adverse events was defined as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product or placebo and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign

(including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. A SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs. Ph2-OL population was included.

End point type	Secondary
End point timeframe:	
From start of study drug administration up to 70 Months	

End point values	Phase 2: Open Label-selinexor			
Subject group type	Reporting group			
Number of subjects analysed	24			
Units: Subjects				
Subjects with TEAEs	24			
Subjects with Serious TEAEs	13			

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 3 Double Blind: Change from Baseline in Quality-of-life Questionnaire 30 Item (QLQ-C30)

End point title	Phase 3 Double Blind: Change from Baseline in Quality-of-life Questionnaire 30 Item (QLQ-C30) ^[18]
-----------------	---

End point description:

TQLQ-C30 was 30-item questionnaire developed to assess quality of life of patients with cancer. QLQ-C30 contains 30 questions that include five functional scales (physical, role, emotional, social, and cognitive functioning); three symptom scales (fatigue, nausea/vomiting and pain), six single-item symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties) and global health status/quality of life (QoL). Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; for functional scales and global health status/QoL, a higher score = better level of functioning (better health status); for symptom scales/items, a higher score = higher level of symptomatology/problems (worse health status). Ph3-ITT. "Overall Subjects analysed"=subjects evaluable for this endpoint. '99999'=standard deviation was not estimated due to single subject.

End point type	Secondary
End point timeframe:	
Baseline up to Day 1387	

Notes:

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Data was assessed and reported for the specific phase only.

End point values	Phase 3 Double- blinded: selinexor	Phase 3 Double- blinded: placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1	0 ^[19]		
Units: Score on a Scale				
arithmetic mean (standard deviation)				
Global health status	33.33 (± 99999)	()		
Physical Functioning	20.0 (± 99999)	()		
Role Functioning	16.67 (± 99999)	()		
Emotional Functioning	8.33 (± 99999)	()		
Social Functioning	50.0 (± 99999)	()		
Cognitive Functioning	0.00 (± 99999)	()		
Fatigue	-22.22 (± 99999)	()		
Nausea and Vomiting	16.67 (± 99999)	()		
Pain	0.0 (± 99999)	()		
Dyspnoea	0.0 (± 99999)	()		
Insomnia	33.33 (± 99999)	()		
Appetite Loss	0.0 (± 99999)	()		
Constipation	0.0 (± 99999)	()		
Diarrhoea	33.33 (± 99999)	()		
Financial Difficulties	-66.67 (± 99999)	()		

Notes:

[19] - Zero Subjects were assessed for Placebo arm.

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 3 Open Label: Change from Baseline in Quality-of-life Questionnaire 30 Item (QLQ-C30)

End point title	Phase 3 Open Label: Change from Baseline in Quality-of-life Questionnaire 30 Item (QLQ-C30)
End point description:	
<p>TQLQ-C30 was 30-item questionnaire developed to assess quality of life of patients with cancer. QLQ-C30 contains 30 questions that include five functional scales (physical, role, emotional, social, and cognitive functioning); three symptom scales (fatigue, nausea/vomiting and pain), six single-item symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties) and global health status/quality of life (QoL). Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; for functional scales and global health status/QoL, a higher score = better level of functioning (better health status); for symptom scales/items, a higher score = higher level of symptomatology/problems (worse health status). Ph3-ITT. "Overall Subjects analysed"=subjects evaluable for this endpoint. '99999'=standard deviation was not estimated due to single subject.</p>	
End point type	Secondary
End point timeframe:	
Baseline up to Day 379	

End point values	Phase 3: Open Label-selinexor			
Subject group type	Reporting group			
Number of subjects analysed	1			
Units: Score on a Scale				
arithmetic mean (standard deviation)				
Global health status	-16.67 (± 99999)			
Physical Functioning	-40.00 (± 99999)			
Role Functioning	-33.33 (± 99999)			
Emotional Functioning	0.0 (± 99999)			
Social Functioning	-50.0 (± 99999)			
Cognitive Functioning	-16.67 (± 99999)			
Fatigue	66.67 (± 99999)			
Nausea and Vomiting	0.0 (± 99999)			
Pain	0.0 (± 99999)			
Dyspnoea	0.0 (± 99999)			
Insomnia	0.0 (± 99999)			
Appetite Loss	0.0 (± 99999)			
Constipation	0.0 (± 99999)			
Diarrhoea	0.0 (± 99999)			
Financial Difficulties	100.0 (± 99999)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From start of study drug administration up to 70 months

Adverse event reporting additional description:

The Ph2-SAF and Ph3-SA consisted of all subjects who had received at least one dose of blinded study treatment in Phase 2 and Phase 3 respectively. The Phase 3 open-label population (Ph3-OL) and Phase 2 open-label Population (Ph2-OL) consisted of all subjects in Phase 3 and Phase 2 respectively, who were randomised to placebo in the blinded.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.0
--------------------	------

Reporting groups

Reporting group title	Phase 2 Double-blinded: selinexor
-----------------------	-----------------------------------

Reporting group description:

Subjects received a fixed blinding dose of 60 mg selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle.

Reporting group title	Phase 2 Double-blinded: placebo
-----------------------	---------------------------------

Reporting group description:

Subjects received a fixed blinding dose of placebo matched to selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle.

Reporting group title	Phase 2 Open-label: selinexor
-----------------------	-------------------------------

Reporting group description:

Subjects in the placebo group who had PD during Phase 2 double-blinded treatment were entered in open-label and received selinexor 60 mg tablet twice-weekly during Weeks 1 to 6 of each 6-week (42-day) cycle.

Reporting group title	Phase 3 Double-blinded: placebo
-----------------------	---------------------------------

Reporting group description:

Subjects received a fixed blinding dose of placebo matched to selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle.

Reporting group title	Phase 3 Open-label: selinexor
-----------------------	-------------------------------

Reporting group description:

Subjects in the placebo group who had PD during Phase 3 double-blinded treatment, were entered in open-label and received selinexor 60 mg tablet twice-weekly during Weeks 1 to 6 of each 6-week (42-day) cycle.

Reporting group title	Phase 3 Double-blinded: selinexor
-----------------------	-----------------------------------

Reporting group description:

Subjects received a fixed blinding dose of 60 mg selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle.

Serious adverse events	Phase 2 Double-blinded: selinexor	Phase 2 Double-blinded: placebo	Phase 2 Open-label: selinexor
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 27 (14.81%)	6 / 30 (20.00%)	13 / 24 (54.17%)
number of deaths (all causes)	18	25	20
number of deaths resulting from adverse events	0	1	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			

Cancer pain			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myelodysplastic syndrome			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour pain			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral ischaemia			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	1 / 24 (4.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous thrombosis			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Complication associated with device			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Fatigue			
subjects affected / exposed	0 / 27 (0.00%)	1 / 30 (3.33%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	1 / 27 (3.70%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	1 / 24 (4.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden death			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	1 / 24 (4.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	2 / 24 (8.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary oedema			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	1 / 24 (4.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			

Confusional state			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	1 / 24 (4.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mania			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device breakage			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Ejection fraction decreased			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transaminases increased			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Anastomotic ulcer haemorrhage			

subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clavicle fracture			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facial bones fracture			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fracture			
subjects affected / exposed	1 / 27 (3.70%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head injury			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Limb injury			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			

subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal fracture			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound complication			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	1 / 24 (4.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Cardiac failure			
subjects affected / exposed	0 / 27 (0.00%)	1 / 30 (3.33%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac ventricular thrombosis			
subjects affected / exposed	0 / 27 (0.00%)	1 / 30 (3.33%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			

subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lethargy			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 27 (3.70%)	0 / 30 (0.00%)	1 / 24 (4.17%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Cataract			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	1 / 24 (4.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal tear			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	1 / 24 (4.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Constipation			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocutaneous fistula			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal obstruction			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			

subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intra-abdominal haemorrhage			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine perforation			
subjects affected / exposed	0 / 27 (0.00%)	1 / 30 (3.33%)	1 / 24 (4.17%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Nausea			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	3 / 24 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstruction gastric			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal obstruction			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestine obstruction			
subjects affected / exposed	0 / 27 (0.00%)	1 / 30 (3.33%)	2 / 24 (8.33%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stomatitis			

subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	1 / 24 (4.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	2 / 24 (8.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Bile duct obstruction			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangitis			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperbilirubinaemia			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 27 (0.00%)	1 / 30 (3.33%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			

subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract obstruction			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	1 / 24 (4.17%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscular weakness			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal pain			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bacteraemia			
subjects affected / exposed	0 / 27 (0.00%)	1 / 30 (3.33%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Bronchitis			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis viral			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia infection			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung abscess			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			

subjects affected / exposed	0 / 27 (0.00%)	2 / 30 (6.67%)	2 / 24 (8.33%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia klebsiella			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 27 (0.00%)	1 / 30 (3.33%)	1 / 24 (4.17%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			

subjects affected / exposed	1 / 27 (3.70%)	0 / 30 (0.00%)	1 / 24 (4.17%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	1 / 27 (3.70%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypocalcaemia			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malnutrition			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Phase 3 Double-blinded: placebo	Phase 3 Open-label: selinexor	Phase 3 Double-blinded: selinexor
Total subjects affected by serious adverse events			
subjects affected / exposed	18 / 97 (18.56%)	25 / 63 (39.68%)	73 / 187 (39.04%)
number of deaths (all causes)	67	43	127
number of deaths resulting from adverse events	3	2	4
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myelodysplastic syndrome			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	2 / 187 (1.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1

Tumour pain			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	2 / 187 (1.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral ischaemia			
subjects affected / exposed	0 / 97 (0.00%)	1 / 63 (1.59%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 97 (0.00%)	2 / 63 (3.17%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism			
subjects affected / exposed	0 / 97 (0.00%)	1 / 63 (1.59%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous thrombosis			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Complication associated with device			
subjects affected / exposed	0 / 97 (0.00%)	1 / 63 (1.59%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 97 (0.00%)	1 / 63 (1.59%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	2 / 187 (1.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Multiple organ dysfunction syndrome			
subjects affected / exposed	1 / 97 (1.03%)	0 / 63 (0.00%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	1 / 97 (1.03%)	1 / 63 (1.59%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	1 / 97 (1.03%)	0 / 63 (0.00%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden death			
subjects affected / exposed	1 / 97 (1.03%)	0 / 63 (0.00%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	1 / 97 (1.03%)	1 / 63 (1.59%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	1 / 97 (1.03%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Hypoxia			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 97 (0.00%)	1 / 63 (1.59%)	3 / 187 (1.60%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	2 / 187 (1.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	1 / 97 (1.03%)	3 / 63 (4.76%)	2 / 187 (1.07%)
occurrences causally related to treatment / all	0 / 1	0 / 3	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary oedema			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 97 (0.00%)	1 / 63 (1.59%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 97 (0.00%)	1 / 63 (1.59%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mania			

subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device breakage			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Ejection fraction decreased			
subjects affected / exposed	0 / 97 (0.00%)	1 / 63 (1.59%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transaminases increased			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Anastomotic ulcer haemorrhage			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clavicle fracture			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facial bones fracture			
subjects affected / exposed	0 / 97 (0.00%)	1 / 63 (1.59%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Fall			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fracture			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head injury			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Limb injury			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal fracture			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound complication			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			

Atrial fibrillation			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	2 / 187 (1.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac ventricular thrombosis			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lethargy			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	2 / 187 (1.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			

Anaemia			
subjects affected / exposed	0 / 97 (0.00%)	2 / 63 (3.17%)	3 / 187 (1.60%)
occurrences causally related to treatment / all	0 / 0	2 / 2	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 97 (0.00%)	2 / 63 (3.17%)	2 / 187 (1.07%)
occurrences causally related to treatment / all	0 / 0	2 / 2	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Cataract			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	2 / 187 (1.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal tear			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 97 (1.03%)	1 / 63 (1.59%)	7 / 187 (3.74%)
occurrences causally related to treatment / all	0 / 1	0 / 1	1 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	1 / 97 (1.03%)	0 / 63 (0.00%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	1 / 97 (1.03%)	0 / 63 (0.00%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Enterocutaneous fistula			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 97 (0.00%)	1 / 63 (1.59%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal obstruction			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	1 / 97 (1.03%)	2 / 63 (3.17%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intra-abdominal haemorrhage			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine perforation			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			

subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	4 / 187 (2.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	4 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstruction gastric			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 97 (0.00%)	1 / 63 (1.59%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal obstruction			
subjects affected / exposed	1 / 97 (1.03%)	0 / 63 (0.00%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestine obstruction			
subjects affected / exposed	2 / 97 (2.06%)	2 / 63 (3.17%)	2 / 187 (1.07%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stomatitis			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	2 / 187 (1.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	1 / 97 (1.03%)	0 / 63 (0.00%)	2 / 187 (1.07%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Bile duct obstruction			

subjects affected / exposed	0 / 97 (0.00%)	1 / 63 (1.59%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangitis			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperbilirubinaemia			
subjects affected / exposed	0 / 97 (0.00%)	1 / 63 (1.59%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 97 (1.03%)	2 / 63 (3.17%)	3 / 187 (1.60%)
occurrences causally related to treatment / all	1 / 1	0 / 2	2 / 3
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Haematuria			
subjects affected / exposed	0 / 97 (0.00%)	1 / 63 (1.59%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	0 / 97 (0.00%)	1 / 63 (1.59%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	1 / 97 (1.03%)	0 / 63 (0.00%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract obstruction			
subjects affected / exposed	1 / 97 (1.03%)	0 / 63 (0.00%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			

Back pain			
subjects affected / exposed	2 / 97 (2.06%)	0 / 63 (0.00%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscular weakness			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal pain			
subjects affected / exposed	1 / 97 (1.03%)	0 / 63 (0.00%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bacteraemia			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 97 (0.00%)	1 / 63 (1.59%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis viral			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	2 / 187 (1.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	1 / 97 (1.03%)	1 / 63 (1.59%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			

subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia infection			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	2 / 187 (1.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung abscess			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pneumonia			
subjects affected / exposed	0 / 97 (0.00%)	1 / 63 (1.59%)	3 / 187 (1.60%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia klebsiella			
subjects affected / exposed	1 / 97 (1.03%)	0 / 63 (0.00%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 97 (0.00%)	1 / 63 (1.59%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			

subjects affected / exposed	2 / 97 (2.06%)	1 / 63 (1.59%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Upper respiratory tract infection			
subjects affected / exposed	1 / 97 (1.03%)	0 / 63 (0.00%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	1 / 97 (1.03%)	1 / 63 (1.59%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 97 (1.03%)	1 / 63 (1.59%)	2 / 187 (1.07%)
occurrences causally related to treatment / all	1 / 1	1 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	2 / 187 (1.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	2 / 187 (1.07%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypocalcaemia			
subjects affected / exposed	0 / 97 (0.00%)	1 / 63 (1.59%)	0 / 187 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			

subjects affected / exposed	0 / 97 (0.00%)	1 / 63 (1.59%)	2 / 187 (1.07%)
occurrences causally related to treatment / all	0 / 0	1 / 1	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malnutrition			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	1 / 187 (0.53%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Phase 2 Double-blinded: selinexor	Phase 2 Double-blinded: placebo	Phase 2 Open-label: selinexor
Total subjects affected by non-serious adverse events			
subjects affected / exposed	27 / 27 (100.00%)	29 / 30 (96.67%)	24 / 24 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Hot flush			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Hypertension			
subjects affected / exposed	5 / 27 (18.52%)	3 / 30 (10.00%)	3 / 24 (12.50%)
occurrences (all)	5	3	3
Hypotension			
subjects affected / exposed	4 / 27 (14.81%)	3 / 30 (10.00%)	3 / 24 (12.50%)
occurrences (all)	4	3	3
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	1 / 27 (3.70%)	0 / 30 (0.00%)	1 / 24 (4.17%)
occurrences (all)	1	0	1
Chills			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	2 / 24 (8.33%)
occurrences (all)	0	0	2
Fatigue			

subjects affected / exposed	15 / 27 (55.56%)	14 / 30 (46.67%)	18 / 24 (75.00%)
occurrences (all)	15	14	18
General physical health deterioration			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	1 / 27 (3.70%)	3 / 30 (10.00%)	1 / 24 (4.17%)
occurrences (all)	1	3	1
Malaise			
subjects affected / exposed	3 / 27 (11.11%)	1 / 30 (3.33%)	3 / 24 (12.50%)
occurrences (all)	3	1	3
Non-cardiac chest pain			
subjects affected / exposed	0 / 27 (0.00%)	2 / 30 (6.67%)	1 / 24 (4.17%)
occurrences (all)	0	2	1
Oedema peripheral			
subjects affected / exposed	3 / 27 (11.11%)	3 / 30 (10.00%)	3 / 24 (12.50%)
occurrences (all)	3	3	3
Pain			
subjects affected / exposed	1 / 27 (3.70%)	2 / 30 (6.67%)	1 / 24 (4.17%)
occurrences (all)	1	2	1
Pyrexia			
subjects affected / exposed	1 / 27 (3.70%)	4 / 30 (13.33%)	1 / 24 (4.17%)
occurrences (all)	1	4	1
Respiratory, thoracic and mediastinal disorders			
Aspiration			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	2 / 24 (8.33%)
occurrences (all)	0	0	2
Cough			
subjects affected / exposed	4 / 27 (14.81%)	3 / 30 (10.00%)	7 / 24 (29.17%)
occurrences (all)	4	3	7
Dyspnoea			
subjects affected / exposed	0 / 27 (0.00%)	3 / 30 (10.00%)	7 / 24 (29.17%)
occurrences (all)	0	3	7
Epistaxis			

subjects affected / exposed occurrences (all)	3 / 27 (11.11%) 3	1 / 30 (3.33%) 1	0 / 24 (0.00%) 0
Nasal congestion subjects affected / exposed occurrences (all)	3 / 27 (11.11%) 3	1 / 30 (3.33%) 1	1 / 24 (4.17%) 1
Oropharyngeal pain subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1	2 / 30 (6.67%) 2	0 / 24 (0.00%) 0
Pleural effusion subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	2 / 30 (6.67%) 2	0 / 24 (0.00%) 0
Pulmonary embolism subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	0 / 30 (0.00%) 0	2 / 24 (8.33%) 2
Psychiatric disorders Anxiety subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	2 / 30 (6.67%) 2	1 / 24 (4.17%) 1
Confusional state subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1	0 / 30 (0.00%) 0	2 / 24 (8.33%) 2
Depression subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	1 / 30 (3.33%) 1	2 / 24 (8.33%) 2
Insomnia subjects affected / exposed occurrences (all)	2 / 27 (7.41%) 2	1 / 30 (3.33%) 1	2 / 24 (8.33%) 2
Investigations Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	4 / 30 (13.33%) 4	2 / 24 (8.33%) 2
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	6 / 27 (22.22%) 6	2 / 30 (6.67%) 2	3 / 24 (12.50%) 3
Aspartate aminotransferase increased			

subjects affected / exposed occurrences (all)	3 / 27 (11.11%) 3	2 / 30 (6.67%) 2	2 / 24 (8.33%) 2
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	6 / 27 (22.22%) 6	7 / 30 (23.33%) 7	3 / 24 (12.50%) 3
Blood lactate dehydrogenase increased subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1	1 / 30 (3.33%) 1	3 / 24 (12.50%) 3
Electrocardiogram QT prolonged subjects affected / exposed occurrences (all)	2 / 27 (7.41%) 2	0 / 30 (0.00%) 0	0 / 24 (0.00%) 0
International normalised ratio increased subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	2 / 30 (6.67%) 2	0 / 24 (0.00%) 0
Weight decreased subjects affected / exposed occurrences (all)	14 / 27 (51.85%) 14	0 / 30 (0.00%) 0	15 / 24 (62.50%) 15
Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	3 / 27 (11.11%) 3	1 / 30 (3.33%) 1	0 / 24 (0.00%) 0
Cardiac disorders			
Sinus Tachycardia subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	1 / 30 (3.33%) 1	1 / 24 (4.17%) 1
Tachycardia subjects affected / exposed occurrences (all)	2 / 27 (7.41%) 2	0 / 30 (0.00%) 0	0 / 24 (0.00%) 0
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	7 / 27 (25.93%) 7	3 / 30 (10.00%) 3	4 / 24 (16.67%) 4
Dysgeusia subjects affected / exposed occurrences (all)	10 / 27 (37.04%) 10	2 / 30 (6.67%) 2	6 / 24 (25.00%) 6
Headache			

subjects affected / exposed occurrences (all)	4 / 27 (14.81%) 4	3 / 30 (10.00%) 3	3 / 24 (12.50%) 3
Sciatica subjects affected / exposed occurrences (all)	2 / 27 (7.41%) 2	0 / 30 (0.00%) 0	0 / 24 (0.00%) 0
Syncope subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1	0 / 30 (0.00%) 0	0 / 24 (0.00%) 0
Taste disorder subjects affected / exposed occurrences (all)	3 / 27 (11.11%) 3	0 / 30 (0.00%) 0	2 / 24 (8.33%) 2
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	16 / 27 (59.26%) 16	9 / 30 (30.00%) 9	10 / 24 (41.67%) 10
Leukopenia subjects affected / exposed occurrences (all)	9 / 27 (33.33%) 9	1 / 30 (3.33%) 1	5 / 24 (20.83%) 5
Lymphopenia subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	1 / 30 (3.33%) 1	1 / 24 (4.17%) 1
Neutropenia subjects affected / exposed occurrences (all)	8 / 27 (29.63%) 8	1 / 30 (3.33%) 1	6 / 24 (25.00%) 6
Thrombocytopenia subjects affected / exposed occurrences (all)	11 / 27 (40.74%) 11	2 / 30 (6.67%) 2	11 / 24 (45.83%) 11
Ear and labyrinth disorders			
Vertigo subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	0 / 30 (0.00%) 0	2 / 24 (8.33%) 2
Eye disorders			
Cataract subjects affected / exposed occurrences (all)	2 / 27 (7.41%) 2	1 / 30 (3.33%) 1	1 / 24 (4.17%) 1
Photopsia			

subjects affected / exposed	2 / 27 (7.41%)	0 / 30 (0.00%)	1 / 24 (4.17%)
occurrences (all)	2	0	1
Visual Impairment			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Vision Blurred			
subjects affected / exposed	8 / 27 (29.63%)	2 / 30 (6.67%)	9 / 24 (37.50%)
occurrences (all)	8	2	9
Vitreous floaters			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	3 / 24 (12.50%)
occurrences (all)	0	0	3
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	2 / 27 (7.41%)	1 / 30 (3.33%)	2 / 24 (8.33%)
occurrences (all)	2	1	2
Abdominal pain			
subjects affected / exposed	6 / 27 (22.22%)	8 / 30 (26.67%)	5 / 24 (20.83%)
occurrences (all)	6	8	5
Constipation			
subjects affected / exposed	6 / 27 (22.22%)	8 / 30 (26.67%)	6 / 24 (25.00%)
occurrences (all)	6	8	6
Diarrhoea			
subjects affected / exposed	8 / 27 (29.63%)	5 / 30 (16.67%)	7 / 24 (29.17%)
occurrences (all)	8	5	7
Dry mouth			
subjects affected / exposed	1 / 27 (3.70%)	0 / 30 (0.00%)	2 / 24 (8.33%)
occurrences (all)	1	0	2
Dyspepsia			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Flatulence			
subjects affected / exposed	1 / 27 (3.70%)	1 / 30 (3.33%)	0 / 24 (0.00%)
occurrences (all)	1	1	0
Nausea			
subjects affected / exposed	24 / 27 (88.89%)	10 / 30 (33.33%)	20 / 24 (83.33%)
occurrences (all)	24	10	20

Gastroesophageal reflux disease subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1	1 / 30 (3.33%) 1	1 / 24 (4.17%) 1
Vomiting subjects affected / exposed occurrences (all)	15 / 27 (55.56%) 15	4 / 30 (13.33%) 4	14 / 24 (58.33%) 14
Hepatobiliary disorders Hyperbilirubinaemia subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1	2 / 30 (6.67%) 2	0 / 24 (0.00%) 0
Skin and subcutaneous tissue disorders Night sweats subjects affected / exposed occurrences (all)	3 / 27 (11.11%) 3	0 / 30 (0.00%) 0	2 / 24 (8.33%) 2
Rash subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	0 / 30 (0.00%) 0	2 / 24 (8.33%) 2
Renal and urinary disorders Haematuria subjects affected / exposed occurrences (all)	3 / 27 (11.11%) 3	0 / 30 (0.00%) 0	0 / 24 (0.00%) 0
Micturition urgency subjects affected / exposed occurrences (all)	2 / 27 (7.41%) 2	0 / 30 (0.00%) 0	0 / 24 (0.00%) 0
Pollakiuria subjects affected / exposed occurrences (all)	2 / 27 (7.41%) 2	0 / 30 (0.00%) 0	0 / 24 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	3 / 27 (11.11%) 3	0 / 30 (0.00%) 0	0 / 24 (0.00%) 0
Back pain subjects affected / exposed occurrences (all)	4 / 27 (14.81%) 4	3 / 30 (10.00%) 3	4 / 24 (16.67%) 4
Muscle spasms			

subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1	0 / 30 (0.00%) 0	1 / 24 (4.17%) 1
Muscular weakness subjects affected / exposed occurrences (all)	2 / 27 (7.41%) 2	0 / 30 (0.00%) 0	3 / 24 (12.50%) 3
Myalgia subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	1 / 30 (3.33%) 1	1 / 24 (4.17%) 1
Pain in extremity subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1	1 / 30 (3.33%) 1	1 / 24 (4.17%) 1
Infections and infestations			
Rhinitis subjects affected / exposed occurrences (all)	2 / 27 (7.41%) 2	0 / 30 (0.00%) 0	1 / 24 (4.17%) 1
Sinusitis subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	0 / 30 (0.00%) 0	2 / 24 (8.33%) 2
Urinary tract infection subjects affected / exposed occurrences (all)	5 / 27 (18.52%) 5	3 / 30 (10.00%) 3	3 / 24 (12.50%) 3
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	15 / 27 (55.56%) 15	5 / 30 (16.67%) 5	14 / 24 (58.33%) 14
Dehydration subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1	1 / 30 (3.33%) 1	3 / 24 (12.50%) 3
Hypercreatininaemia subjects affected / exposed occurrences (all)	4 / 27 (14.81%) 4	5 / 30 (16.67%) 5	7 / 24 (29.17%) 7
Hyperglycaemia subjects affected / exposed occurrences (all)	9 / 27 (33.33%) 9	3 / 30 (10.00%) 3	2 / 24 (8.33%) 2
Hyperkalaemia			

subjects affected / exposed	0 / 27 (0.00%)	2 / 30 (6.67%)	4 / 24 (16.67%)
occurrences (all)	0	2	4
Hyperuricaemia			
subjects affected / exposed	0 / 27 (0.00%)	0 / 30 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Hypoalbuminaemia			
subjects affected / exposed	4 / 27 (14.81%)	5 / 30 (16.67%)	1 / 24 (4.17%)
occurrences (all)	4	5	1
Hypocalcaemia			
subjects affected / exposed	4 / 27 (14.81%)	0 / 30 (0.00%)	1 / 24 (4.17%)
occurrences (all)	4	0	1
Hypokalaemia			
subjects affected / exposed	2 / 27 (7.41%)	4 / 30 (13.33%)	1 / 24 (4.17%)
occurrences (all)	2	4	1
Hypochloraemia			
subjects affected / exposed	3 / 27 (11.11%)	0 / 30 (0.00%)	3 / 24 (12.50%)
occurrences (all)	3	0	3
Hypomagnesaemia			
subjects affected / exposed	3 / 27 (11.11%)	3 / 30 (10.00%)	3 / 24 (12.50%)
occurrences (all)	3	3	3
Hyponatraemia			
subjects affected / exposed	9 / 27 (33.33%)	6 / 30 (20.00%)	10 / 24 (41.67%)
occurrences (all)	9	6	10
Hypophosphataemia			
subjects affected / exposed	3 / 27 (11.11%)	1 / 30 (3.33%)	1 / 24 (4.17%)
occurrences (all)	3	1	1

Non-serious adverse events	Phase 3 Double-blinded: placebo	Phase 3 Open-label: selinexor	Phase 3 Double-blinded: selinexor
Total subjects affected by non-serious adverse events			
subjects affected / exposed	94 / 97 (96.91%)	62 / 63 (98.41%)	186 / 187 (99.47%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			
subjects affected / exposed	4 / 97 (4.12%)	4 / 63 (6.35%)	4 / 187 (2.14%)
occurrences (all)	4	4	4
Vascular disorders			

Hot flush			
subjects affected / exposed	3 / 97 (3.09%)	4 / 63 (6.35%)	3 / 187 (1.60%)
occurrences (all)	3	4	3
Hypertension			
subjects affected / exposed	10 / 97 (10.31%)	6 / 63 (9.52%)	22 / 187 (11.76%)
occurrences (all)	10	6	22
Hypotension			
subjects affected / exposed	3 / 97 (3.09%)	5 / 63 (7.94%)	23 / 187 (12.30%)
occurrences (all)	3	5	23
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	10 / 97 (10.31%)	13 / 63 (20.63%)	58 / 187 (31.02%)
occurrences (all)	10	13	58
Chills			
subjects affected / exposed	7 / 97 (7.22%)	1 / 63 (1.59%)	11 / 187 (5.88%)
occurrences (all)	7	1	11
Fatigue			
subjects affected / exposed	31 / 97 (31.96%)	33 / 63 (52.38%)	96 / 187 (51.34%)
occurrences (all)	31	33	96
General physical health deterioration			
subjects affected / exposed	2 / 97 (2.06%)	4 / 63 (6.35%)	2 / 187 (1.07%)
occurrences (all)	2	4	2
Influenza like illness			
subjects affected / exposed	1 / 97 (1.03%)	0 / 63 (0.00%)	3 / 187 (1.60%)
occurrences (all)	1	0	3
Malaise			
subjects affected / exposed	2 / 97 (2.06%)	1 / 63 (1.59%)	2 / 187 (1.07%)
occurrences (all)	2	1	2
Non-cardiac chest pain			
subjects affected / exposed	2 / 97 (2.06%)	2 / 63 (3.17%)	5 / 187 (2.67%)
occurrences (all)	2	2	5
Oedema peripheral			
subjects affected / exposed	12 / 97 (12.37%)	10 / 63 (15.87%)	30 / 187 (16.04%)
occurrences (all)	12	10	30
Pain			

subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	4 / 187 (2.14%)
occurrences (all)	0	0	4
Pyrexia			
subjects affected / exposed	9 / 97 (9.28%)	8 / 63 (12.70%)	20 / 187 (10.70%)
occurrences (all)	9	8	20
Respiratory, thoracic and mediastinal disorders			
Aspiration			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	0 / 187 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	7 / 97 (7.22%)	7 / 63 (11.11%)	30 / 187 (16.04%)
occurrences (all)	7	7	30
Dyspnoea			
subjects affected / exposed	11 / 97 (11.34%)	10 / 63 (15.87%)	34 / 187 (18.18%)
occurrences (all)	11	10	34
Epistaxis			
subjects affected / exposed	0 / 97 (0.00%)	1 / 63 (1.59%)	6 / 187 (3.21%)
occurrences (all)	0	1	6
Nasal congestion			
subjects affected / exposed	0 / 97 (0.00%)	4 / 63 (6.35%)	7 / 187 (3.74%)
occurrences (all)	0	4	7
Oropharyngeal pain			
subjects affected / exposed	1 / 97 (1.03%)	1 / 63 (1.59%)	7 / 187 (3.74%)
occurrences (all)	1	1	7
Pleural effusion			
subjects affected / exposed	0 / 97 (0.00%)	3 / 63 (4.76%)	2 / 187 (1.07%)
occurrences (all)	0	3	2
Pulmonary embolism			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	5 / 187 (2.67%)
occurrences (all)	0	0	5
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 97 (0.00%)	4 / 63 (6.35%)	6 / 187 (3.21%)
occurrences (all)	0	4	6
Confusional state			

subjects affected / exposed occurrences (all)	1 / 97 (1.03%) 1	1 / 63 (1.59%) 1	6 / 187 (3.21%) 6
Depression subjects affected / exposed occurrences (all)	2 / 97 (2.06%) 2	5 / 63 (7.94%) 5	11 / 187 (5.88%) 11
Insomnia subjects affected / exposed occurrences (all)	4 / 97 (4.12%) 4	2 / 63 (3.17%) 2	21 / 187 (11.23%) 21
Investigations			
Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all)	3 / 97 (3.09%) 3	4 / 63 (6.35%) 4	4 / 187 (2.14%) 4
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	5 / 97 (5.15%) 5	6 / 63 (9.52%) 6	16 / 187 (8.56%) 16
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	5 / 97 (5.15%) 5	7 / 63 (11.11%) 7	11 / 187 (5.88%) 11
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	10 / 97 (10.31%) 10	5 / 63 (7.94%) 5	14 / 187 (7.49%) 14
Blood lactate dehydrogenase increased subjects affected / exposed occurrences (all)	1 / 97 (1.03%) 1	1 / 63 (1.59%) 1	0 / 187 (0.00%) 0
Electrocardiogram QT prolonged subjects affected / exposed occurrences (all)	0 / 97 (0.00%) 0	0 / 63 (0.00%) 0	5 / 187 (2.67%) 5
International normalised ratio increased subjects affected / exposed occurrences (all)	2 / 97 (2.06%) 2	3 / 63 (4.76%) 3	5 / 187 (2.67%) 5
Weight decreased subjects affected / exposed occurrences (all)	9 / 97 (9.28%) 9	25 / 63 (39.68%) 25	81 / 187 (43.32%) 81
Blood creatine phosphokinase increased			

subjects affected / exposed occurrences (all)	3 / 97 (3.09%) 3	4 / 63 (6.35%) 4	5 / 187 (2.67%) 5
Cardiac disorders			
Sinus Tachycardia subjects affected / exposed occurrences (all)	6 / 97 (6.19%) 6	6 / 63 (9.52%) 6	7 / 187 (3.74%) 7
Tachycardia subjects affected / exposed occurrences (all)	3 / 97 (3.09%) 3	4 / 63 (6.35%) 4	3 / 187 (1.60%) 3
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	6 / 97 (6.19%) 6	11 / 63 (17.46%) 11	45 / 187 (24.06%) 45
Dysgeusia subjects affected / exposed occurrences (all)	4 / 97 (4.12%) 4	12 / 63 (19.05%) 12	51 / 187 (27.27%) 51
Headache subjects affected / exposed occurrences (all)	3 / 97 (3.09%) 3	7 / 63 (11.11%) 7	23 / 187 (12.30%) 23
Sciatica subjects affected / exposed occurrences (all)	3 / 97 (3.09%) 3	1 / 63 (1.59%) 1	1 / 187 (0.53%) 1
Syncope subjects affected / exposed occurrences (all)	0 / 97 (0.00%) 0	3 / 63 (4.76%) 3	11 / 187 (5.88%) 11
Taste disorder subjects affected / exposed occurrences (all)	1 / 97 (1.03%) 1	5 / 63 (7.94%) 5	8 / 187 (4.28%) 8
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	22 / 97 (22.68%) 22	26 / 63 (41.27%) 26	91 / 187 (48.66%) 91
Leukopenia subjects affected / exposed occurrences (all)	1 / 97 (1.03%) 1	13 / 63 (20.63%) 13	26 / 187 (13.90%) 26
Lymphopenia			

subjects affected / exposed occurrences (all)	4 / 97 (4.12%) 4	6 / 63 (9.52%) 6	14 / 187 (7.49%) 14
Neutropenia subjects affected / exposed occurrences (all)	1 / 97 (1.03%) 1	12 / 63 (19.05%) 12	38 / 187 (20.32%) 38
Thrombocytopenia subjects affected / exposed occurrences (all)	5 / 97 (5.15%) 5	24 / 63 (38.10%) 24	72 / 187 (38.50%) 72
Ear and labyrinth disorders Vertigo subjects affected / exposed occurrences (all)	2 / 97 (2.06%) 2	0 / 63 (0.00%) 0	4 / 187 (2.14%) 4
Eye disorders Cataract subjects affected / exposed occurrences (all)	1 / 97 (1.03%) 1	2 / 63 (3.17%) 2	7 / 187 (3.74%) 7
Photopsia subjects affected / exposed occurrences (all)	0 / 97 (0.00%) 0	1 / 63 (1.59%) 1	9 / 187 (4.81%) 9
Visual Impairment subjects affected / exposed occurrences (all)	0 / 97 (0.00%) 0	1 / 63 (1.59%) 1	10 / 187 (5.35%) 10
Vision Blurred subjects affected / exposed occurrences (all)	3 / 97 (3.09%) 3	8 / 63 (12.70%) 8	42 / 187 (22.46%) 42
Vitreous floaters subjects affected / exposed occurrences (all)	1 / 97 (1.03%) 1	1 / 63 (1.59%) 1	0 / 187 (0.00%) 0
Gastrointestinal disorders Abdominal distension subjects affected / exposed occurrences (all)	6 / 97 (6.19%) 6	1 / 63 (1.59%) 1	11 / 187 (5.88%) 11
Abdominal pain subjects affected / exposed occurrences (all)	30 / 97 (30.93%) 30	13 / 63 (20.63%) 13	49 / 187 (26.20%) 49
Constipation			

subjects affected / exposed	23 / 97 (23.71%)	14 / 63 (22.22%)	74 / 187 (39.57%)
occurrences (all)	23	14	74
Diarrhoea			
subjects affected / exposed	17 / 97 (17.53%)	18 / 63 (28.57%)	75 / 187 (40.11%)
occurrences (all)	17	18	75
Dry mouth			
subjects affected / exposed	1 / 97 (1.03%)	3 / 63 (4.76%)	11 / 187 (5.88%)
occurrences (all)	1	3	11
Dyspepsia			
subjects affected / exposed	6 / 97 (6.19%)	4 / 63 (6.35%)	18 / 187 (9.63%)
occurrences (all)	6	4	18
Flatulence			
subjects affected / exposed	1 / 97 (1.03%)	1 / 63 (1.59%)	10 / 187 (5.35%)
occurrences (all)	1	1	10
Nausea			
subjects affected / exposed	38 / 97 (39.18%)	45 / 63 (71.43%)	151 / 187 (80.75%)
occurrences (all)	38	45	151
Gastroesophageal reflux disease			
subjects affected / exposed	1 / 97 (1.03%)	0 / 63 (0.00%)	11 / 187 (5.88%)
occurrences (all)	1	0	11
Vomiting			
subjects affected / exposed	12 / 97 (12.37%)	31 / 63 (49.21%)	93 / 187 (49.73%)
occurrences (all)	12	31	93
Hepatobiliary disorders			
Hyperbilirubinaemia			
subjects affected / exposed	2 / 97 (2.06%)	4 / 63 (6.35%)	3 / 187 (1.60%)
occurrences (all)	2	4	3
Skin and subcutaneous tissue disorders			
Night sweats			
subjects affected / exposed	0 / 97 (0.00%)	0 / 63 (0.00%)	13 / 187 (6.95%)
occurrences (all)	0	0	13
Rash			
subjects affected / exposed	5 / 97 (5.15%)	0 / 63 (0.00%)	5 / 187 (2.67%)
occurrences (all)	5	0	5
Renal and urinary disorders			

Haematuria subjects affected / exposed occurrences (all)	7 / 97 (7.22%) 7	0 / 63 (0.00%) 0	7 / 187 (3.74%) 7
Micturition urgency subjects affected / exposed occurrences (all)	1 / 97 (1.03%) 1	0 / 63 (0.00%) 0	1 / 187 (0.53%) 1
Pollakiuria subjects affected / exposed occurrences (all)	3 / 97 (3.09%) 3	0 / 63 (0.00%) 0	6 / 187 (3.21%) 6
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	5 / 97 (5.15%) 5	3 / 63 (4.76%) 3	9 / 187 (4.81%) 9
Back pain subjects affected / exposed occurrences (all)	12 / 97 (12.37%) 12	7 / 63 (11.11%) 7	26 / 187 (13.90%) 26
Muscle spasms subjects affected / exposed occurrences (all)	3 / 97 (3.09%) 3	1 / 63 (1.59%) 1	12 / 187 (6.42%) 12
Muscular weakness subjects affected / exposed occurrences (all)	2 / 97 (2.06%) 2	5 / 63 (7.94%) 5	11 / 187 (5.88%) 11
Myalgia subjects affected / exposed occurrences (all)	7 / 97 (7.22%) 7	1 / 63 (1.59%) 1	9 / 187 (4.81%) 9
Pain in extremity subjects affected / exposed occurrences (all)	4 / 97 (4.12%) 4	5 / 63 (7.94%) 5	11 / 187 (5.88%) 11
Infections and infestations			
Rhinitis subjects affected / exposed occurrences (all)	0 / 97 (0.00%) 0	0 / 63 (0.00%) 0	1 / 187 (0.53%) 1
Sinusitis subjects affected / exposed occurrences (all)	2 / 97 (2.06%) 2	2 / 63 (3.17%) 2	2 / 187 (1.07%) 2
Urinary tract infection			

subjects affected / exposed occurrences (all)	8 / 97 (8.25%) 8	4 / 63 (6.35%) 4	13 / 187 (6.95%) 13
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	21 / 97 (21.65%)	32 / 63 (50.79%)	114 / 187 (60.96%)
occurrences (all)	21	32	114
Dehydration			
subjects affected / exposed	3 / 97 (3.09%)	3 / 63 (4.76%)	11 / 187 (5.88%)
occurrences (all)	3	3	11
Hypercreatininaemia			
subjects affected / exposed	13 / 97 (13.40%)	9 / 63 (14.29%)	42 / 187 (22.46%)
occurrences (all)	13	9	42
Hyperglycaemia			
subjects affected / exposed	8 / 97 (8.25%)	7 / 63 (11.11%)	21 / 187 (11.23%)
occurrences (all)	8	7	21
Hyperkalaemia			
subjects affected / exposed	2 / 97 (2.06%)	5 / 63 (7.94%)	13 / 187 (6.95%)
occurrences (all)	2	5	13
Hyperuricaemia			
subjects affected / exposed	2 / 97 (2.06%)	4 / 63 (6.35%)	5 / 187 (2.67%)
occurrences (all)	2	4	5
Hypoalbuminaemia			
subjects affected / exposed	8 / 97 (8.25%)	5 / 63 (7.94%)	10 / 187 (5.35%)
occurrences (all)	8	5	10
Hypocalcaemia			
subjects affected / exposed	4 / 97 (4.12%)	4 / 63 (6.35%)	8 / 187 (4.28%)
occurrences (all)	4	4	8
Hypokalaemia			
subjects affected / exposed	5 / 97 (5.15%)	1 / 63 (1.59%)	20 / 187 (10.70%)
occurrences (all)	5	1	20
Hypochloraemia			
subjects affected / exposed	2 / 97 (2.06%)	2 / 63 (3.17%)	6 / 187 (3.21%)
occurrences (all)	2	2	6
Hypomagnesaemia			
subjects affected / exposed	2 / 97 (2.06%)	1 / 63 (1.59%)	24 / 187 (12.83%)
occurrences (all)	2	1	24

Hyponatraemia			
subjects affected / exposed	8 / 97 (8.25%)	11 / 63 (17.46%)	52 / 187 (27.81%)
occurrences (all)	8	11	52
Hypophosphataemia			
subjects affected / exposed	3 / 97 (3.09%)	7 / 63 (11.11%)	13 / 187 (6.95%)
occurrences (all)	3	7	13

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
11 March 2016	Protocol Amendment 1: Inclusion criterion #7 was changed due to radiologic evidence of disease progression within 6 months prior to randomization. If the subject received other intervening therapy after documented disease progression, further disease progression was to be documented after the completion of the intervening therapy. This change was consistent with information provided to clinical sites in a memorandum dated 28 Jan 2016. To remove the requirement for a second biopsy collected from adolescent/pediatric subjects for exploratory studies if there appears to be a potential for serious risk for the subject.
01 November 2016	Protocol Amendment 2: Added PFS according to the Investigator based on clinical and/or radiologic criteria as a secondary objective for Phase 3 and revised the order of the secondary efficacy objectives and endpoints for Phase 2 (revised efficacy endpoint order: TTP, ORR, DOR, tumor glucose metabolism) and Phase 3 (revised efficacy endpoint order: OS, TTP, QoL, ORR, DOR, PFS according to the Investigator). Randomization of subject was updated to stratify based on the number of prior systemic therapies (1 vs ≥ 2) and prior eribulin use (prior eribulin vs no prior eribulin) as requested by EMA SAWP. Clarified the purpose of the analysis of PFS at the end of Phase 2. The analysis of PFS at the end of Phase 2 was used as a guideline on whether or not to continue enrolling patients in Phase 3.
06 July 2017	Protocol Amendment 3: Added an exception to the requirement that subjects would either continue study drug until PD was confirmed by the IRC or discontinue study drug, complete the EoT Visit, and be followed for survival.
29 September 2017	Protocol Amendment 4: The evaluation of response and progression of disease was changed from WHO to RECIST v1.1 as agreed to with the FDA. Updated the inclusion criteria to clarify the documentation for DDLS that was required for eligibility, added an exception to the radiologic evidence of PD requirement for subjects who discontinued their most recent treatment after no more than 1 dose, and changed the renal function threshold. Added pregnancy testing (serum hCG or high sensitivity urine) for premenopausal females of childbearing potential prior to dosing on Day 1 of Cycles ≥ 2 while on treatment. Updated the supportive care guidance (including TLS) and standard safety language. Aligned the definition of progression-free survival (PFS) for the primary objectives and broadened secondary and exploratory endpoint definitions.
23 August 2018	Protocol Amendment 5: Moved the exclusion for subjects who have a circulating lymphocyte count of $>50,000/\mu\text{L}$ from an inclusion criterion to an exclusion criterion and specified that it applied only to subjects in France.
10 September 2018	Protocol Amendment 6: Updated the language based on results from Study KCP-330-003 that demonstrated that food does not affect the PK parameters of selinexor. Acute cerebellar syndrome is no longer considered to be an important potential risk for selinexor. Corrected the definition of PFS. Revised SAE reporting to the DSMB. Removed censoring rule for OS for non-inferiority. Revised PFS according to the Investigator. Revised exclusion criterion #6 regarding hepatitis.
30 January 2020	Protocol Amendment 7: Increased the number of enrolled subjects in the Phase 3 portion of the study to approximately 277 subjects sample size recalculated due to increased accrual period.
21 May 2020	Protocol Amendment 8: Efficacy and QoL endpoints were modified. Added outcome of interim analysis. Exploratory endpoints PFS, ORR, and DOR, tumor response at 6 weeks FDG-PET (Phase 2 only) and CT (diagnostic), and PFS2 were removed.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported